Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality

被引:35
作者
Larranaga, N. [1 ]
Galceran, J. [2 ]
Ardanaz, E. [3 ]
Franch, P. [4 ]
Navarro, C. [5 ]
Sanchez, M. J. [6 ]
Pastor-Barriuso, R. [7 ]
机构
[1] Basque Country Reg Author, Publ Hlth Dept Gipuzkoa, Basque Country Canc Registry, San Sebastian, Spain
[2] Pere Virgili Hlth Res Inst, Fdn Soc Canc Res & Prevent, Tarragona Canc Registry, Reus, Spain
[3] Navarre Publ Hlth Inst, Navarre Canc Registry, Pamplona, Spain
[4] Directorate Gen Publ Hlth & Participat, Dept Epidemiol, Mallorca Canc Registry, Palma De Mallorca, Spain
[5] Hlth Author, Dept Epidemiol, Murcia Canc Registry, Murcia, Spain
[6] Andalusian Sch Publ Hlth, Granada Canc Registry, Granada, Spain
[7] Carlos III Inst Hlth, Natl Ctr Epidemiol, Madrid, Spain
关键词
incidence; mortality; prostate neoplasms; Spain; PSA; trends; INTERPRETING TRENDS; SURVEILLANCE SERIES; RISING INCIDENCE; RISK; OVERDIAGNOSIS; SURVIVAL; DECREASE; EPIDEMIOLOGY; DIAGNOSIS; AUSTRIA;
D O I
10.1093/annonc/mdq087
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Materials and methods: The time trend in invasive prostate cancer incidence from 1975 to 2004 was studied by combining data from 13 Spanish population-based cancer registries. Change-point Poisson regression models were fitted for all men and for two age groups (45-64 and 65+ years). Age-period-cohort models were used to study cohort and period effects. In addition, we studied the time trend in prostate cancer mortality in Spain for the period 1980-2007. Results: Incidence increased annually by 1.3% from 1975 to 1990 and by 7.3% thereafter. Until 1990, the percentage increase was low and indeed similar for both age groups. While the subsequent increase in the two age groups was greater, this was particularly marked among the youngest men, with a decrease being observed in age groups > 85 years in the last quinquennium. Mortality increased by an annual figure of 0.7% until 1998, after which it decreased by 3.6% per annum until 2007. Conclusions: Despite the dramatic rise in incidence from 1990 onwards, mainly due to opportunistic screening, prostate cancer mortality was only observed to decline slowly from 1998. If prostate-specific antigen screening remains at a similar level in Spain, overdiagnosis may well become an important chronic side-effect and health problem.
引用
收藏
页码:iii83 / iii89
页数:7
相关论文
共 50 条
  • [21] Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era
    Konety, BR
    Bird, VY
    Deorah, S
    Dahmoush, L
    JOURNAL OF UROLOGY, 2005, 174 (05) : 1785 - 1788
  • [22] Midlife baseline prostate-specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality
    Cirulli, Giuseppe Ottone
    Davis, Matthew
    Stephens, Alex
    Chiarelli, Giuseppe
    Finati, Marco
    Chase, Morrison
    Tinsley, Shane
    Arora, Sohrab
    Sood, Akshay
    Lughezzani, Giovanni
    Buffi, Nicolo
    Carrieri, Giuseppe
    Salonia, Andrea
    Briganti, Alberto
    Montorsi, Francesco
    Rogers, Craig
    Abdollah, Firas
    CANCER, 2025, 131 (01)
  • [23] Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Revisiting the Evidence
    Carter, H. Ballentine
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (18): : 1866 - 1868
  • [24] Utility of total prostate-specific antigen and free prostate-specific antigen index to detect prostate cancer in the asymptomatic patient
    Rivera-Sanchez, Roberto
    Parre-Mendez, Carlos
    Luisa Caballero-Juradoc, Maria
    Flores-Paz, Rocio
    ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2022, 56 (01): : 11 - 15
  • [25] Pattern, Clinical Characteristics, and Impact of Family History on Prostate-Specific Antigen in Prostate Cancer: A Multicenter Study
    Iheanacho, Chinonyerem O.
    Odili, Valentine U.
    Enakirerhi, Glen E.
    Isiwele, Edoise M.
    Essiet, Akanimo
    AMERICAN JOURNAL OF MENS HEALTH, 2024, 18 (04)
  • [26] Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia
    Luo, Qingwei
    Yu, Xue Qin
    Kahn, Clare
    Egger, Sam
    Patel, Manish, I
    Grogan, Paul B.
    Caruana, Michael
    Canfell, Karen
    Smith, David P.
    O'Connell, Dianne L.
    CANCER EPIDEMIOLOGY, 2022, 78
  • [27] Further Evidence That Prostate-Specific Antigen Screening Reduces Prostate Cancer Mortality
    Stampfer, Meir J.
    Jahn, Jaquelyn L.
    Gann, Peter H.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (03):
  • [28] Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer
    Iyer, Hari S.
    Stone, Benjamin V.
    Roscoe, Charlotte
    Hsieh, Mei-Chin
    Stroup, Antoinette M.
    Wiggins, Charles L.
    Schumacher, Fredrick R.
    Gomez, Scarlett L.
    Rebbeck, Timothy R.
    Trinh, Quoc-Dien
    JAMA NETWORK OPEN, 2024, 7 (06)
  • [29] Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis
    Pathirana, Thanya
    Sequeira, Rehan
    Del Mar, Chris
    Dickinson, James A.
    Armstrong, Bruce K.
    Bell, Katy J. L.
    Glasziou, Paul
    CANCER EPIDEMIOLOGY, 2022, 77
  • [30] Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing
    Oberaigner, Willi
    Horninger, Wolfgang
    Klocker, Helmut
    Schoenitzer, Dieter
    Stuehlinger, Wolf
    Bartsch, Georg
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2006, 164 (04) : 376 - 384